In this article, we will discuss Panobinostat (1). So, let’s get started.
Panobinostat is a medication used in the treatment of certain types of cancer, particularly multiple myeloma. It belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors. These drugs work by interfering with the activity of enzymes that play a role in the regulation of gene expression. By inhibiting HDAC, Panobinostat can modify the acetylation status of proteins, including histones, leading to changes in gene transcription.
Indications:
Panobinostat is primarily used in combination with other medications for the treatment of multiple myeloma in patients who have received prior therapies.
Mechanism of Action:
HDAC inhibitors like Panobinostat work by blocking the activity of histone deacetylases, leading to an increase in the acetylation of histones. This modification can alter gene expression and impact the regulation of cell growth and survival.
Administration:
Panobinostat is typically administered orally in the form of capsules.
Clinical Trials and Approval:
Panobinostat underwent clinical trials for multiple myeloma, and based on positive results, it received approval from regulatory agencies, such as the U.S. Food and Drug Administration (FDA).